You are here: Industry Insights > Immunomedics

News List

Gilead Sciences acquires Immunomedics in $21bn deal pharmaceutical-technology
October 28, 2020
Gilead Sciences has completed the previously announced acquisition of cancer therapies developer Immunomedics for approximately $21bn.
Gilead may soon buy Immunomedics in deal over $20 billion expresspharma
September 24, 2020
The deal, which will expand Gilead’s oncology portfolio, might get announced tomorrow if not sooner, inform reports.
Trodelvy from Immunomedics extends survival in breast cancer patients expresspharma
September 21, 2020
The FDA granted the drug accelerated approval for its use in metastatic triple-negative breast cancer (mTNBC) patients who had previously received at least two prior therapies.
Gilead agrees to acquire Immunomedics for $21bn pharmaceutical-technology
September 15, 2020
Gilead Sciences has signed a definitive agreement to acquire cancer therapies developer Immunomedics for a total consideration of approximately $21bn, or $88 per share.
Immunomedics Announces Promotion Agreement With Janssen for Erdafitinib in the U.S. firstwordpharma
April 09, 2019
Under the terms of the agreement, Immunomedics' sales team will provide product detailing from the launch……
Immunomedics appoints new CMO biospectrumasia
April 11, 2018
Dr. Iannone brings more than thirteen years of experience in clinical drug development, including the approval of several targeted and immuno-oncology medicines at AstraZeneca/MedImmune and Merck & Co.